Literature DB >> 11736955

Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism.

J O'Donnell1, A D Mumford, R A Manning, M A Laffan.   

Abstract

Elevated plasma factor VIII coagulant activity (FVIII:C, > 150 IU/dl) is a risk factor for venous thromboembolism (VTE). We hypothesized that increased FVIII:C may exert a prothrombotic effect by increasing basal thrombin generation. To test this hypothesis we have measured prothrombin fragment 1 + 2 (F1 + 2) and thrombin-antithrombin complex (TAT) in three groups: (i) patients with objectively confirmed VTE and elevated FVIII:C; (ii) patients with VTE and no detectable thrombophilia; and (iii) healthy age- and sex-matched control subjects. In the group of patients with elevated FVIII:C, TAT and F1 + 2 levels were increased in 85% and 78% of individuals respectively. This frequency of coagulation activation is dramatically higher than that reported for other recognized constitutional thrombophilias. In the group of patients with VTE but no proven thrombophilia, increased thrombin generation was present in 30% of individuals. Basal thrombin generation was significantly higher in patients with elevated FVIII:C compared with individuals with VTE but no documented thrombophilia (median TAT = 8.65 microg/l versus 2.95 microg/l, median F1 + 2 = 1.5 nmol/l versus 0.87 nmol/l; P < 0.0001, P < 0.001). Overall FVIII:C levels were strongly correlated with levels of thrombin generation (r= 0.5, P < 0001). The clinical significance of such markedly increased F1 + 2 and TAT levels in patients with high FVIII:C levels remains unclear.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11736955     DOI: 10.1046/j.1365-2141.2001.03146.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

1.  In vitro modeling of the influence of FVIII activity and heparin induced prolongation of APTT.

Authors:  Aida Mehmedagić; Selma Skrbo; Dzenita Softić; Midhat Haracić
Journal:  Bosn J Basic Med Sci       Date:  2005-08       Impact factor: 3.363

2.  Myocardial infarction and factor VIII elevation in a 36-year-old man.

Authors:  Amit Alam; Harsh Doshi; Divya N Patel; Keval Patel; Dreamy James; Jesus Almendral
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-09-15

3.  Acute Ischemic Stroke in an Eight-Year-Old Male With Elevated Factor VIII Activity and SARS-CoV-2 Antibodies.

Authors:  Seth J Deskins; Matthew Mamone; Samuel Luketich; Arin Jennings; Sydney Downey; Jacob Gelman; Richard Brant; Collin John
Journal:  Cureus       Date:  2022-05-13

Review 4.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

Review 5.  Global assays of hemostasis.

Authors:  Kathleen E Brummel-Ziedins; Alisa S Wolberg
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

6.  Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery.

Authors:  M Byrne; J V Reynolds; J S O'Donnell; M Keogan; B White; M Byrne; S Murphy; S G Maher; G P Pidgeon
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

7.  Post splenectomy fatal pulmonary embolism in a patient with moderate hemophilia a.

Authors:  Abdolhossein Davoodabadi; Mohammad Mahdi Adib; Behrooz Keleidari
Journal:  Iran J Med Sci       Date:  2011-06

8.  Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.

Authors:  Lars L F G Valke; Laura H Bukkems; Wideke Barteling; Britta A P Laros-van Gorkom; Nicole M A Blijlevens; Ron A A Mathôt; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2020-10-21       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.